# Vir Biotechnology share price today (Vir Biotechnology, Inc., VIR)

> Vir Biotechnology, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. VIR · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/vir

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $11.02 (+114.8% in a year)
- Revenue (Jun 2026): ₹0.2 B (+19,582.5% on a year ago)
- Profit (Jun 2026): ₹0.1 B
- ROE: −57%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Vir Biotechnology share price today? Vir Biotechnology, Inc.'s share price was $11.02 at the close on 5 November 2026. That is 14.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between $5 and $12, and at that close it sat 90% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 13 weeks in a row. Over the last 1 year the share price moved +95% while the S&P 500 moved +18%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Vir Biotechnology pay? Vir Biotechnology, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Vir Biotechnology on? Vir Biotechnology is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Vir Biotechnology profitable? Vir Biotechnology, Inc. earned ₹0.1 B of net profit in the Jun 2026 quarter. The full FY25 year was a loss of ₹0.4 B. That is 33.5% of the quarter's revenue. The same quarter a year earlier lost ₹0.1 B. 11 of the last 12 reported quarters were loss-making. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Vir Biotechnology make, and is it growing? Vir Biotechnology, Inc. reported ₹0.2 B of revenue in the Jun 2026 quarter, +19,582.5% on the same quarter a year earlier. Over 4 years it has grown −50.0% a year on average. The last full year, FY25, came in at ₹0.1 B. The last four reported quarters add to ₹0.3 B. FY25 revenue was ₹0.1 B, −7.6% on the year before. Recent pace: the last four quarters grew +4,952.4% on average, against −50.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +1,495.9%, against +96.1% a year over the last 8 quarters (accelerating). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Vir Biotechnology keep? Vir Biotechnology, Inc.'s sales have fallen to very little: FY25 revenue was ₹0.1 B, against ₹1.6 B in FY22. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is Vir Biotechnology's profit turning into cash? Over the last 2 years, 155% of Vir Biotechnology, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 its operations used ₹0.4 B of cash, against −₹0.4 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.4 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Vir Biotechnology's cash go? Vir Biotechnology, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Vir Biotechnology's P/E ratio, and how does it compare with its own history? Vir Biotechnology, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Vir Biotechnology business getting better or worse? Vir Biotechnology, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Vir Biotechnology earn on its capital? Vir Biotechnology, Inc. earned a ROE of −57% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −201%, a number that says nothing useful about the business. ## Does Vir Biotechnology have too much debt? Vir Biotechnology, Inc. has total debt of ₹0.1 B against shareholder equity of ₹1.0 B as of Jun 2026, so its debt is 0.09× its equity, which is very little. Year by year, that ratio went from 0.10 in FY21 to 0.13 in FY25. So the returns on this page come from the business, not from borrowed money. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Vir Biotechnology shareholding pattern? 12.5% of Vir Biotechnology, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 7.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Vir Biotechnology from balance-sheet trouble? For Vir Biotechnology, Inc., the Z-score is 1.29. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.29 is inside the danger zone, so the balance sheet is a real risk. ## How does Vir Biotechnology rank in its industry? There is no score against its industry: Vir Biotechnology, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Vir Biotechnology compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Vir Biotechnology in size? Vir Biotechnology is the 79th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Fortrea Holdings Inc., Mesoblast and Harmony Biosciences Holdings, Inc. Just below it: Sarepta Therapeutics, Inc., Maravai LifeSciences Holdings, Inc. and Stoke Therapeutics, Inc. ### Biotechnology companies close in size

1. [Fortrea Holdings Inc.](https://www.sectoralpha.in/us/stocks/ftre) $2 billion
2. [Mesoblast Limited](https://www.sectoralpha.in/us/stocks/meso) $2 billion
3. [Harmony Biosciences Holdings, Inc.](https://www.sectoralpha.in/us/stocks/hrmy) $1.9 billion
4. Vir Biotechnology, Inc. $1.9 billion
5. [Sarepta Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/srpt) $1.9 billion
6. [Maravai LifeSciences Holdings, Inc.](https://www.sectoralpha.in/us/stocks/mrvi) $1.8 billion
7. [Stoke Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/stok) $1.7 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Monarch Casino & Resort, Inc.](https://www.sectoralpha.in/us/stocks/mcri) $2 billion · Resorts & Casinos
2. [Establishment Labs Holdings Inc.](https://www.sectoralpha.in/us/stocks/esta) $2 billion · Medical Devices
3. Vir Biotechnology, Inc. $2 billion
4. [Aehr Test Systems, Inc.](https://www.sectoralpha.in/us/stocks/aehr) $2 billion · Semiconductor Equipment & Materials
5. [Innospec Inc.](https://www.sectoralpha.in/us/stocks/iosp) $2 billion · Specialty Chemicals

## What else do people ask about Vir Biotechnology? ### What were Vir Biotechnology's latest quarterly results? Vir Biotechnology, Inc. reported revenue of ₹0.2 B and net profit of ₹0.1 B for the Jun 2026 quarter. The operating margin was 30.7%, 9,799.2 percentage points higher than a year earlier (as of 5 November 2026). ### What is Vir Biotechnology's profit? Vir Biotechnology, Inc. earned ₹0.1 B of net profit in the Jun 2026 quarter. Full-year FY25 profit was −₹0.4 B. The operating margin was 30.7% in the latest quarter (as of 5 November 2026). ### What is Vir Biotechnology's market cap? Vir Biotechnology, Inc.'s market capitalisation is $1.9 B at a stock price of $11.02. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Vir Biotechnology performing? Vir Biotechnology, Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 13 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Vir Biotechnology's stock price go up? This page does not forecast Vir Biotechnology, Inc.'s stock price. What it shows instead: the stock price is $11.02. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Is Vir Biotechnology's profit real cash? Yes, over the last 2 years, 155% of Vir Biotechnology, Inc.'s reported profit came in as cash from operations. The latest year was lower at 89%, so the trend is worth watching. In FY25, operating cash was −₹0.4 B against reported profit of −₹0.4 B. Most of that cash then goes into a mix of the daily operating cycle and new capacity. These are yearly figures (as of 5 November 2026). ### What could break the Vir Biotechnology story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Vir Biotechnology a stock worth studying right now? What the numbers show: Vir Biotechnology, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.